Goldman Sachs completed the acquisition of a minority stake in Aragen Life Sciences from ChrysCapital.

Goldman Sachs, a global investment banking, securities and investment management firm, completed the acquisition of a minority stake in Aragen Life Sciences, a contract research organization, from ChrysCapital, an India focused investment firm. Financial terms were not disclosed. “We believe this new investment at this important juncture in our company’s development underscores the tremendous opportunity ahead. Working with Goldman Sachs, we are well-positioned to address the opportunities in front of us to become a leading, global player with comprehensive end-to-end solutions for drug discovery and development. For more than five years, ChrysCapital has been a trusted investment partner. Following their successful exit, we are pleased to now enter a new phase in our continued evolution," Manni Kantipudi, Aragen Life Sciences CEO.